Akshata Sharma
Share
PharmEasy-owned diagnostics platform Thyrocare posted a profit after tax of INR 23.5 Cr in Q1 FY25, up 35% year-on-year from 17.4 Cr in the same quarter of the previous fiscal
Revenue from operations surged 16.3% to INR 156.9 Cr during the June quarter of the ongoing fiscal year from INR 134.9 Cr in Q1 FY24.
The company said that revenues from pathology and radiology segments rose 16% YoY and 15% YOY, respectively, for the quarter ended June 30, 2024. Sequentially, the company's profit after tax and operating income jumped 36% and 2%, respectively.
Consolidated reported EBITDA stood at INR 42 Cr during the quarter under review, up 21% from INR 34.7 Cr in Q1 FY24.
Shares of Thyrocare hit a 20% upper circuit and touched a new 52-week high at INR 780.10 apiece on the BSE today after the company announced its Q1 results.
--Advertisement--
